Sherlock Biosciences

Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.

Jim J. Collins

Co-Founder and Director

1 past transactions

Sense Biodetection

Acquisition in 2023
Sense Biodetection Limited is a molecular diagnostics company focused on improving healthcare decisions and processes by developing novel, user-centred, handheld tests in the fields of infections and oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.